Table 1. Statistical analysis of relapse in diffuse large B cell lymphoma patients whose miR-92a levels were determined at complete response phase.

			univariate			multivariate
Factors at diagnosis	No. (n = 34*)	Relpased (n = 6)	P value	odds ratio	95% CI	P value	Corrected odds ratio	95% CI
Sex
male	13	1	.231	0.267	0.02743 to 2.592	.833	1.3037	0.066 to 8.971
female	21	5
Age
≥60 years	20	4	1	1.5	0.2346 to 9.593	.50	0.418	0.03 to 5.287
<60 years	14	2
LDH
Elevated	16	4	.289	2.667	0.4170 to 17.05	.673	1.625	0.170 to 15.522
Normal	18	2
B symptoms
Yes	16	3	.874	1.154	0.1976 to 6.738	.853	0.730	0.026 to 20.544
No	18	3
Clinical stage
III+IV	18	5	.18	5.769	0.5946 to 55.98	.062	23.189	0.858 to 629.583
I+II	16	1
International Prognostic Index
high + high-int	14	3	.628	1.545	0.2629 to 9.085	.972	0.943	0.038 to 23.744
low + low int	20	3
Plasma miR-92a
Low (<0.2165)	12	5	.007	15	1.486 to 151.4	.020	16.232	1.562 to 168.725
Normal (≥0.2165)	22	1

Abbreviations: CI, confidence interval; LDH, lactate dehydrogenase.

*Patients who had been followed for more than 6 months and who did not receive any hematopoietic stem cell transplantation were analyzed.